Clinical trials: Prostate Cancer (Adenocarcinoma)
Metastatic Castrate-Resistant Prostate Cancer (mCRPC),, Efficacy,
Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.
To investigate the safety, tolerability and anti-tumour activity of AZD5363, as monotherapy, in patients with metastatic Castrate-Resistant Prostate Cancer.
- Conditions
- Metastatic Castrate-Resistant Prostate Cancer (mCRPC),, Efficacy,, Safety and Tolerability,, Pharmacokinetics,
- Trial name
- PYRUS (NCT01692262)
- Testing
- Intermittent dosing of AZD5363
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 59 people
- Sponsor
- AstraZeneca
Prostatic Neoplasm, Prostate Cancer
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
The main purpose of this study was to determine whether ADT started before or after sipuleucel-T led to a better immune system response.
- Conditions
- Prostatic Neoplasm, Prostate Cancer, Prostatic Adenocarcinoma
- Trial name
- NCT01431391
- Testing
- sipuleucel-T, leuprolide acetate
- Where
- 14 sites in United States
- Volunteers
- 68 people
- Sponsor
- Dendreon
Prostate Cancer, Melanoma
Safety Study of MGA271 in Refractory Cancer
The purpose of this study is to evaluate the safety of MGA271 when given by intravenous (IV) infusion to patients with refractory cancer.
- Conditions
- Prostate Cancer, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer
- Trial name
- NCT01391143
- Testing
- MGA271
- Where
- 12 sites in United States
- Volunteers
- 179 people
- Sponsor
- MacroGenics
Prostate Cancer Metastatic
Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer
Phase 1/2 dose escalation study to assess the safety and tolerability of ARV-110 in men with mCRPC who have progressed on prior approved systemic therapies for their castrate resistant disease (one of which must be enzalutamide…
- Trial name
- mCRPC (NCT03888612)
- Testing
- ARV-110
- Where
- 54 sites in United States
- Volunteers
- 248 people
- Sponsor
- Arvinas Inc.
Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous, Urothelial Carcinoma
- Trial name
- NCT05585034
- Testing
- XmAb®808, Keytruda® (pembrolizumab)
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Xencor, Inc.
Prostate Cancer
Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer
This is a Multicenter, Open Label, Phase 2 Study of Sipuleucel-T in Men with Metastatic Castrate Resistant Prostate Cancer (CRPC).
- Trial name
- NCT00901342
- Testing
- sipuleucel-T
- Where
- 18 sites in United States
- Volunteers
- 104 people
- Sponsor
- Dendreon
Prostate Cancer
A Study of 99mTc-MIP-1404 and 99mTc-MIP-1405 in Patients With Metastatic Prostate Adenocarcinoma and Healthy Volunteers
This is a single-blind, randomized, cross-over design. Patients with metastatic prostate adenocarcinoma; newly diagnosed, high-risk patients with prostate adenocarcinoma; and healthy subjects will be administered a single…
- Trial name
- NCT01261754
- Testing
- 99mTc MIP 1404, 99mTc MIP 1405
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Disease Progression
Treatment Resistance Following Anti-cancer Therapies
The TRANSLATE study aims to better understand why tumors become resistant to standard anti-cancer therapies. New tumor biopsy and blood samples are collected after disease progression on standard-of-care anti-cancer treatment and…
- Trial name
- NCT04436120
- Testing
- De novo tumor tissue biopsy, Research blood draws
- Where
- 33 sites in United States, Argentina and 3 more
- Volunteers
- 38 people
- Sponsor
- Pfizer
Prostatic Neoplasms
G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer
A single-arm, open-label Phase II clinical trial to evaluate the effect of G-202 on the perfusion and volume of the prostate using non-invasive multiparametric prostate magnetic resonance imaging (mpMRI).
- Trial name
- NCT02381236
- Testing
- G-202
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- GenSpera, Inc.
Colorectal Cancer, Cholangiocarcinoma
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).
- Conditions
- Colorectal Cancer, Cholangiocarcinoma, Appendiceal Adenocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT06399757
- Testing
- APL-5125
- Where
- 9 sites in United States
- Volunteers
- 27 people
- Sponsor
- Apollo Therapeutics Ltd
Small Cell Lung Cancer Metastatic or Locally Advanced, Neuroendocrine Cancer
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms
- Conditions
- Small Cell Lung Cancer Metastatic or Locally Advanced, Neuroendocrine Cancer, Metastatic Neuroendocrine Prostate Cancer, Metastatic Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
- Trial name
- NCT07080242
- Testing
- BL-M14D1
- Where
- 31 sites in United States, Georgia and 1 more
- Volunteers
- 120 people
- Sponsor
- SystImmune Inc.
Prostatic Neoplasms
Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration resistant prostate cancer.
- Trial name
- NCT04428788
- Testing
- CC-94676, CC1083611, CC1083610
- Where
- 19 sites in United States
- Volunteers
- 131 people
- Sponsor
- Celgene
Motor Function, Cognitive Function
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA.
- Conditions
- Motor Function, Cognitive Function, Contrast Media
- Trial name
- ODYSSEY (NCT04373564)
- Testing
- Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain
- Where
- 51 sites in United States, Brazil and 6 more
- Volunteers
- 2,076 people
- Sponsor
- Guerbet
Brest Cancer, Lung Cancer (NSCLC)
The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients.
- Conditions
- Brest Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Adult, Prostate Cancers
- Trial name
- CCANED-CIPHER (NCT06717295)
- Testing
- DiNanoQ: A multi-cancer early detection (MCED) blood test, DiNanoTrack: Therapeutic Response Monitoring Blood Test
- Where
- 4 sites in Argentina, Nigeria and 1 more
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Javier Toledo
Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.
- Conditions
- Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Lung Cancer (Non-Small Cell)
- Trial name
- NCT07145255
- Testing
- ADC
- Where
- 7 sites in United States
- Volunteers
- 150 people
- Sponsor
- MBrace Therapeutics
Metastatic Prostate Cancer
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.
- Trial name
- NCT06800313
- Testing
- JNJ-101556143 Formulation 1, JNJ-101556143 Formulation 2, JNJ-101556143 Formulation 3
- Where
- 18 sites in United States, United Kingdom
- Volunteers
- 190 people
- Sponsor
- Janssen Research & Development, LLC
Pancreatic Cancer, Breast Cancer
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT05311618
- Testing
- NGM438, Pembrolizumab (KEYTRUDA ®)
- Where
- 6 sites in United States
- Volunteers
- 71 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Prostate Cancer
PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy
PROSTVAC-VF is an investigational cancer vaccine. The vaccine is based on the theory that the immune system can be taught to fight cancer by directing the immune system to attack specific targets found on cancer cells.
- Trial name
- NCT00078585
- Testing
- PROSTVAC®-VF/TRICOM™
- Where
- 47 sites in United States
- Volunteers
- 120 people
- Sponsor
- Bavarian Nordic
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer, Lung Cancer
- Trial name
- NCT04383210
- Testing
- Seribantumab
- Where
- 42 sites in United States, Australia and 2 more
- Volunteers
- 54 people
- Sponsor
- Elevation Oncology
Bladder Cancer, Prostate Cancer
Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO)
This study will evaluate the safety and performance of the Medtronic Hugo™ RAS System when used for urologic RAS procedures.
- Conditions
- Bladder Cancer, Prostate Cancer, Kidney Cancer, Pelvic Tumor
- Trial name
- NCT05696444
- Testing
- RAS Prostatectomy, RAS Cystectomy, RAS Nephrectomy
- Where
- 6 sites in United States
- Volunteers
- 144 people
- Sponsor
- Medtronic - MITG